Tags

Type your tag names separated by a space and hit enter

Localized mucosal response to intranasal live attenuated influenza vaccine in adults.
J Infect Dis 2013; 207(1):115-24JI

Abstract

BACKGROUND

Influenza virus infection is a major public health burden worldwide. Available vaccines include the inactivated intramuscular trivalent vaccine and, more recently, an intranasal live attenuated influenza vaccine (LAIV). The measure of successful vaccination with the inactivated vaccine is a systemic rise in immunoglobulin G (IgG) level, but for the LAIV no such correlate has been established.

METHODS

Seventy-nine subjects were given the LAIV FluMist. Blood was collected prior to vaccination and 3 days and 30 days after vaccination. Nasal wash was collected 3 days and 30 days after vaccination. Responses were measured systemically and in mucosal secretions for cytokines, cell activation profiles, and antibody responses.

RESULTS

Only 9% of subjects who received LAIV seroconverted, while 33% of patients developed at least a 2-fold increase in influenza virus-specific immunoglobulin A (IgA) antibodies in nasal wash. LAIV induced a localized inflammation, as suggested by increased expression of interferon-response genes in mucosal RNA and increased granulocyte colony-stimulating factor (G-CSF) and IP-10 in nasal wash. Interestingly, patients who seroconverted had significantly lower serum levels of G-CSF before vaccination.

CONCLUSIONS

Protection by LAIV is likely provided through mucosal IgA and not by increases in systemic IgG. LAIV induces local inflammation. Seroconversion is achieved in a small fraction of subjects with a lower serum G-CSF level.

Authors+Show Affiliations

Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23087433

Citation

Barría, Maria Ines, et al. "Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults." The Journal of Infectious Diseases, vol. 207, no. 1, 2013, pp. 115-24.
Barría MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013;207(1):115-24.
Barría, M. I., Garrido, J. L., Stein, C., Scher, E., Ge, Y., Engel, S. M., ... Moran, T. M. (2013). Localized mucosal response to intranasal live attenuated influenza vaccine in adults. The Journal of Infectious Diseases, 207(1), pp. 115-24. doi:10.1093/infdis/jis641.
Barría MI, et al. Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults. J Infect Dis. 2013 Jan 1;207(1):115-24. PubMed PMID: 23087433.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Localized mucosal response to intranasal live attenuated influenza vaccine in adults. AU - Barría,Maria Ines, AU - Garrido,Jose Luis, AU - Stein,Cheryl, AU - Scher,Erica, AU - Ge,Yongchao, AU - Engel,Stephanie M, AU - Kraus,Thomas A, AU - Banach,David, AU - Moran,Thomas M, Y1 - 2012/10/19/ PY - 2012/10/23/entrez PY - 2012/10/23/pubmed PY - 2013/3/1/medline SP - 115 EP - 24 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 207 IS - 1 N2 - BACKGROUND: Influenza virus infection is a major public health burden worldwide. Available vaccines include the inactivated intramuscular trivalent vaccine and, more recently, an intranasal live attenuated influenza vaccine (LAIV). The measure of successful vaccination with the inactivated vaccine is a systemic rise in immunoglobulin G (IgG) level, but for the LAIV no such correlate has been established. METHODS: Seventy-nine subjects were given the LAIV FluMist. Blood was collected prior to vaccination and 3 days and 30 days after vaccination. Nasal wash was collected 3 days and 30 days after vaccination. Responses were measured systemically and in mucosal secretions for cytokines, cell activation profiles, and antibody responses. RESULTS: Only 9% of subjects who received LAIV seroconverted, while 33% of patients developed at least a 2-fold increase in influenza virus-specific immunoglobulin A (IgA) antibodies in nasal wash. LAIV induced a localized inflammation, as suggested by increased expression of interferon-response genes in mucosal RNA and increased granulocyte colony-stimulating factor (G-CSF) and IP-10 in nasal wash. Interestingly, patients who seroconverted had significantly lower serum levels of G-CSF before vaccination. CONCLUSIONS: Protection by LAIV is likely provided through mucosal IgA and not by increases in systemic IgG. LAIV induces local inflammation. Seroconversion is achieved in a small fraction of subjects with a lower serum G-CSF level. SN - 1537-6613 UR - https://www.unboundmedicine.com/medline/citation/23087433/Localized_mucosal_response_to_intranasal_live_attenuated_influenza_vaccine_in_adults_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jis641 DB - PRIME DP - Unbound Medicine ER -